HMD’s plans for 2022

HMD’s top priority right now is to help the government combat the pandemic. HMD had been ensuring continuity of supply chain and its manufacturing plants to ensure no shortages in India for its critically needed disposable devices during the Covid crisis. HMD remains dedicated to its constant endeavor to introduce affordable new and advanced products that not just ensure patient safety but also the safety of healthcare professionals.

In our utmost endeavor to make India Covid-syringe surplus, HMD’s manufacturing plants are operational 24×7. It is a race against time to help ramp up capacity of our cannulas (needle points) and needle capillary tubing manufacturing. A new 150,000 sq ft factory as a green field project is being set to be commissioned by January 2022 to increase capacity from 4 billion cannulas (needle points) per annum to 6 billion per annum to be Atmanirbhar, a vision we share with the Hon’ble Prime Minister.

From day one, as an essential-product supplier and having more than 60 percent market share in the country, we knew that the country depended on us. Predicting a spike in demand, in April 2020 itself, we started to rapidly ramp up HMD’s capacity and re-engineered the standard disposable syringes lines to manufacture in their place auto disposable syringe for vaccination. HMD initiated in May 2020 an investment of over USD 15 million (approx. ₹100 crore) from their own resources, without government support to mass produce specialty syringes even before purchase orders were in sight. A similar second round of investment of another ₹100 crore is being done in 2021–22.

HMD has supplied approximately 640 million 0.5 mL AD syringes to the government by December 2021 to help vaccinate over 855 million people till date to support the massive vaccination campaign to eradicate Covid-19 and help make India Atmanirbhar. In addition, HMD exported approximately 300 million AD syringes to COVAX and PAHO in 2021, and nearly 50 million syringes to Japan for Covid vaccination.

HMD alone contributes to over 65 percent of syringe supplies in India for curative healthcare and immunization. Presently, HMD is producing more than 475,000 syringes of various types per hour at its factories spread over 11 acres in Faridabad industrial district in Haryana.

By March 2022, HMD aims to ramp up capacities to 1.5 billion pieces of AD syringes while simultaneously increasing its total syringe capacity to 4.5 billion pieces a year.

By April 2022, HMD will introduce a range of syringes with safety needle to prevent needle-stick injury, for the global market.

HMD is coming up with more designs of novel safety-engineered drug delivery products in the near future, e.g., for nasal vaccine delivery that does not need a needle and some that need a needle but do not need a syringe.

Adaptability and the ability to think ahead are skills that have clearly served HMD well.

HMD has deliberately remained focused on a very narrow product range of medical disposables that need high level of assembly automation in order to ensure it delivers premium products that are created in partnership with some of the best suppliers worldwide. We believe in ethics and following fair business practices and empower each of our employees to think and act as if it’s his own company while working as a team player and every salesperson is our brand ambassador.

Over two decades, HMD created a niche for their disposable syringe – DISPOVAN, which is today still the most popular brand in syringe market in India with over 60-percent market share with DispoVan needle and DispoVan insulin syringes having over 70-percent market share, and thereby displaced renowned MNCs – an inspirational case study for other Indian entrepreneurs.

HMD is now a reputed leading top-3 manufacturer of disposable syringes in the world and possibly the largest for Kojak auto disable syringes, and shouldering the responsibilities with the government for the success of India’s massive Covid vaccination campaign. We feel honored to contribute to the national vaccination campaign.

The vaccine bullets need our guns. It is a huge responsibility. We are glad we could shoulder the responsibilities with the government.